Cleveland Clinic released its fourth annual Alzheimer’s Disease (AD) drug development pipeline, showcasing new research for clinicians’ holistic overview of current U.S. research. Few treatment options exist for Alzheimer’s disease as most drug development initiatives don’t make it. There has not been a new drug approved to treat the disease since 2003.
Spearheaded by clinical investigator Jeffrey Cummings MD, ScD, director emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health, he focused on pharmacologic Alzheimer’s trials pipeline from ClinicalTrials.gov.
The team found 132 agents presently in 156 clinical trials—28 of which are in 42 phase III studies; 74 in 83 phase II studies; and 30 in 31 phase I studies.
Alzheimer’s Disease Pipeline
- 19 agents in trials targeting cognitive enhancement
- 14 focusing on neuropsychiatric and behavioral symptoms
- 96 agents in disease modification trials of which 38 focus on amyloid as a primary target or as one of several effects
- 18 small molecules
- 20 are monoclonal antibodies or biological therapies
- 7 small molecules and 10 biologics have tau as either the primary target or as a combination target
New Clinical Trials
The Cleveland Clinic team found new biomarkers and outcomes as well as some innovative trial designs.
Drug development continues robustly at all phases despite significant setbacks in several programs in the recent past. Continuing unmet needs requires a commitment to growing and accelerating the pipeline.